Depotech(depo) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo)

DEPO 7.300

+1.7%

Aug 14 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JCS who wrote (864)	11/16/1998 10:28:00 PM
From: Rudy Saucillo	Read Replies (2) of 887

Several things were different this time. Number one: the application and subsequent ODAC recommendation is for accelerated approval which has different standards than regular approval. Secondly, the efficacy data for DepoCyt in lymphomatous meningitis was clearly no worse than and likely better than the control, ara c, irrespective of how the data was subgrouped and analyzed. Thirdly, DepoTech did an excellent job demonstrating that DepoCyt side effects, while more numerous than ara c, were generally mild and transient. Excellent day for DepoTech. I was at the panel and would like to commend Dr. Stephen Howell (DepoTech's Acting Medical Director) for an extremely effective, rigorous presentation of DepoTech's data. Rudy

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next